<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">660</journal-id><journal-id journal-id-type="pmc-domain">jco</journal-id><journal-id journal-id-type="publisher-id">JCO</journal-id><journal-title-group><journal-title>Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0732-183X</issn><issn pub-type="epub">1527-7755</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10022863</article-id><article-id pub-id-type="pmcid-ver">PMC10022863.1</article-id><article-id pub-id-type="pmcaid">10022863</article-id><article-id pub-id-type="pmcaiid">10022863</article-id><article-id pub-id-type="pmid">36623243</article-id><article-id pub-id-type="doi">10.1200/JCO.22.01239</article-id><article-id pub-id-type="publisher-id">JCO.22.01239</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>ORIGINAL REPORTS</subject><subj-group><subject>Breast Cancer</subject></subj-group></subj-group></article-categories><title-group><article-title>Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4630-9903</contrib-id><name name-style="western"><surname>Yadav</surname><given-names initials="S">Siddhartha</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="con1" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6784-2072</contrib-id><name name-style="western"><surname>Boddicker</surname><given-names initials="NJ">Nicholas J.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3435-1805</contrib-id><name name-style="western"><surname>Na</surname><given-names initials="J">Jie</given-names></name><degrees>MS</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5152-8740</contrib-id><name name-style="western"><surname>Polley</surname><given-names initials="EC">Eric C.</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="con2" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6814-4639</contrib-id><name name-style="western"><surname>Hu</surname><given-names initials="C">Chunling</given-names></name><degrees>PhD</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7714-2734</contrib-id><name name-style="western"><surname>Hart</surname><given-names initials="SN">Steven N.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gnanaolivu</surname><given-names initials="RD">Rohan D.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2129-6934</contrib-id><name name-style="western"><surname>Larson</surname><given-names initials="N">Nicole</given-names></name><degrees>BS</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Holtegaard</surname><given-names initials="S">Susan</given-names></name><degrees>BS</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="H">Huaizhi</given-names></name><degrees>BS</degrees><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dunn</surname><given-names initials="CA">Carolyn A.</given-names></name><degrees>BS</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2419-8536</contrib-id><name name-style="western"><surname>Teras</surname><given-names initials="LR">Lauren R.</given-names></name><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patel</surname><given-names initials="AV">Alpa V.</given-names></name><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="con3" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lacey</surname><given-names initials="JV">James V.</given-names></name><degrees>PhD</degrees><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5053-0390</contrib-id><name name-style="western"><surname>Neuhausen</surname><given-names initials="SL">Susan L.</given-names></name><degrees>PhD</degrees><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6728-1834</contrib-id><name name-style="western"><surname>Martinez</surname><given-names initials="E">Elena</given-names></name><degrees>PhD</degrees><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0097-9971</contrib-id><name name-style="western"><surname>Haiman</surname><given-names initials="C">Christopher</given-names></name><degrees>ScD</degrees><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1679-9932</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="F">Fei</given-names></name><degrees>PhD</degrees><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6298-332X</contrib-id><name name-style="western"><surname>Ruddy</surname><given-names initials="KJ">Kathryn J.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="con4" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olson</surname><given-names initials="JE">Janet E.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="con5" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3259-8003</contrib-id><name name-style="western"><surname>John</surname><given-names initials="EM">Esther M.</given-names></name><degrees>PhD</degrees><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6175-9470</contrib-id><name name-style="western"><surname>Kurian</surname><given-names initials="AW">Allison W.</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref><xref rid="con6" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6776-0018</contrib-id><name name-style="western"><surname>Sandler</surname><given-names initials="DP">Dale P.</given-names></name><degrees>PhD</degrees><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1931-1349</contrib-id><name name-style="western"><surname>O'Brien</surname><given-names initials="KM">Katie M.</given-names></name><degrees>PhD</degrees><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5303-6398</contrib-id><name name-style="western"><surname>Taylor</surname><given-names initials="JA">Jack A.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weinberg</surname><given-names initials="CR">Clarice R.</given-names></name><degrees>PhD</degrees><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9603-0110</contrib-id><name name-style="western"><surname>Anton-Culver</surname><given-names initials="H">Hoda</given-names></name><degrees>PhD</degrees><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4529-3727</contrib-id><name name-style="western"><surname>Ziogas</surname><given-names initials="A">Argyrios</given-names></name><degrees>PhD</degrees><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1417-5349</contrib-id><name name-style="western"><surname>Zirpoli</surname><given-names initials="G">Gary</given-names></name><degrees>PhD</degrees><xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0697-9347</contrib-id><name name-style="western"><surname>Goldgar</surname><given-names initials="DE">David E.</given-names></name><degrees>PhD</degrees><xref rid="aff15" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6534-335X</contrib-id><name name-style="western"><surname>Palmer</surname><given-names initials="JR">Julie R.</given-names></name><degrees>ScD</degrees><xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5914-7272</contrib-id><name name-style="western"><surname>Domchek</surname><given-names initials="SM">Susan M.</given-names></name><degrees>MD</degrees><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref><xref rid="aff17" ref-type="aff">
<sup>17</sup>
</xref><xref rid="con7" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6714-092X</contrib-id><name name-style="western"><surname>Weitzel</surname><given-names initials="JN">Jeffrey N.</given-names></name><degrees>MD</degrees><xref rid="aff18" ref-type="aff">
<sup>18</sup>
</xref><xref rid="con8" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6740-0901</contrib-id><name name-style="western"><surname>Nathanson</surname><given-names initials="KL">Katherine L.</given-names></name><degrees>MD</degrees><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref><xref rid="aff17" ref-type="aff">
<sup>17</sup>
</xref><xref rid="con9" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4472-8103</contrib-id><name name-style="western"><surname>Kraft</surname><given-names initials="P">Peter</given-names></name><degrees>PhD</degrees><xref rid="aff19" ref-type="aff">
<sup>19</sup>
</xref><xref rid="con10" ref-type="fn"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9417-9985</contrib-id><name name-style="western"><surname>Couch</surname><given-names initials="FJ">Fergus J.</given-names></name><degrees>PhD</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor1" ref-type="corresp"/><xref rid="con11" ref-type="fn"/></contrib><aff id="aff1"><label><sup>1</sup></label>Department of Oncology, Mayo Clinic, Rochester, MN</aff><aff id="aff2"><label><sup>2</sup></label>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN</aff><aff id="aff3"><label><sup>3</sup></label>Department of Public Health Sciences, University of Chicago, Chicago, IL</aff><aff id="aff4"><label><sup>4</sup></label>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN</aff><aff id="aff5"><label><sup>5</sup></label>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN</aff><aff id="aff6"><label><sup>6</sup></label>Department of Population Science, American Cancer Society, Atlanta, GA</aff><aff id="aff7"><label><sup>7</sup></label>Beckman Research Institute of City of Hope, Duarte, CA</aff><aff id="aff8"><label><sup>8</sup></label>Department of Family Medicine and Public Health, University of California, San Diego, CA</aff><aff id="aff9"><label><sup>9</sup></label>Keck School of Medicine, University of Southern California, Los Angeles, CA</aff><aff id="aff10"><label><sup>10</sup></label>Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA</aff><aff id="aff11"><label><sup>11</sup></label>Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA</aff><aff id="aff12"><label><sup>12</sup></label>National Institute of Environmental Health Sciences, Durham, NC</aff><aff id="aff13"><label><sup>13</sup></label>University of California, Irvine, CA</aff><aff id="aff14"><label><sup>14</sup></label>Slone Epidemiology Center at Boston University, Boston, MA</aff><aff id="aff15"><label><sup>15</sup></label>University of Utah, Salt Lake City, UT</aff><aff id="aff16"><label><sup>16</sup></label>Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA</aff><aff id="aff17"><label><sup>17</sup></label>Basser Center for BRCA, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA</aff><aff id="aff18"><label><sup>18</sup></label>Latin American School of Oncology, Sierra Madre, CA</aff><aff id="aff19"><label><sup>19</sup></label>Harvard University T.H. Chan School of Public Health, Boston, MA</aff></contrib-group><author-notes><corresp id="cor1">Fergus J. Couch, PhD, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Mayo Clinic, Rochester, MN 55905; e-mail: <email>couch.fergus@mayo.edu</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>20</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>9</day><month>1</month><year>2023</year></pub-date><volume>41</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">431530</issue-id><fpage>1703</fpage><lpage>1713</lpage><history><date date-type="received"><day>27</day><month>5</month><year>2022</year></date><date date-type="rev-recd"><day>3</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>20</day><month>03</month><year>2024</year></date></event><event event-type="pmc-released-under-embargo"><date><day>01</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by American Society of Clinical Oncology</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>American Society of Clinical Oncology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jco-41-1703.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jco-41-1703.pdf"/><abstract><title>PURPOSE</title><p>To estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic>.</p><sec><title>METHODS</title><p>The study population included 15,104 prospectively followed women within the CARRIERS study treated with ipsilateral surgery for invasive breast cancer. The risk of CBC was estimated for PV carriers in each gene compared with women without PVs in a multivariate proportional hazard regression analysis accounting for the competing risk of death and adjusting for patient and tumor characteristics. The primary analyses focused on the overall cohort and on women from the general population. Secondary analyses examined associations by race/ethnicity, age at primary breast cancer diagnosis, menopausal status, and tumor estrogen receptor (ER) status.</p></sec><sec><title>RESULTS</title><p>Germline <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, and <italic toggle="yes">CHEK2</italic> PV carriers with breast cancer were at significantly elevated risk (hazard ratio &gt; 1.9) of CBC, whereas only the <italic toggle="yes">PALB2</italic> PV carriers with ER-negative breast cancer had elevated risks (hazard ratio, 2.9). By contrast, <italic toggle="yes">ATM</italic> PV carriers did not have significantly increased CBC risks. African American PV carriers had similarly elevated risks of CBC as non-Hispanic White PV carriers. Among premenopausal women, the 10-year cumulative incidence of CBC was estimated to be 33% for <italic toggle="yes">BRCA1</italic>, 27% for <italic toggle="yes">BRCA2</italic>, and 13% for <italic toggle="yes">CHEK2</italic> PV carriers with breast cancer and 35% for <italic toggle="yes">PALB2</italic> PV carriers with ER-negative breast cancer. The 10-year cumulative incidence of CBC among postmenopausal PV carriers was 12% for <italic toggle="yes">BRCA1</italic>, 9% for <italic toggle="yes">BRCA2</italic>, and 4% for <italic toggle="yes">CHEK2</italic>.</p></sec><sec><title>CONCLUSION</title><p>Women diagnosed with breast cancer and known to carry germline PVs in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, or <italic toggle="yes">PALB2</italic> are at substantially increased risk of CBC and may benefit from enhanced surveillance and risk reduction strategies.</p></sec></abstract><counts><fig-count count="2"/><table-count count="4"/><equation-count count="0"/><ref-count count="50"/><page-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><title>BACKGROUND</title><p>Among breast cancer survivors, precise estimation of the risk of second breast and other cancers is essential to guide appropriate surveillance and risk-reducing strategies. The risk of contralateral breast cancer (CBC) among women with breast cancer in the general population is estimated to be 0.5% per year,<sup><xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref></sup> with germline mutation status, race/ethnicity, age at diagnosis, and menopausal status significantly influencing the risk.<sup><xref rid="b3" ref-type="bibr">3</xref>-<xref rid="b6" ref-type="bibr">6</xref></sup> Germline pathogenic variants (PVs) in <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> are detected in 5%-7% of women with breast cancer in the general population and are associated with a significantly increased risk of breast cancer in unaffected women.<sup><xref rid="b7" ref-type="bibr">7</xref>-<xref rid="b10" ref-type="bibr">10</xref></sup> The CBC risk among carriers of germline PVs, especially for <italic toggle="yes">ATM</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> PV carriers, is not well-defined. Even for <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> carriers, current CBC risk estimates are primarily derived from high-risk women with breast cancer qualifying for genetic testing because of young age at diagnosis or family history of breast or ovarian cancer and may not apply to women in the general population. Because of the lack of precise understanding of CBC risk, appropriate surgical management and surveillance strategies among breast cancer survivors with predisposition gene PVs have not been well-defined.</p><boxed-text id="B1" position="anchor" orientation="portrait"><sec sec-type="context-box"><title>CONTEXT</title><p>
<list list-type="simple"><list-item><p>
<bold>Key Objective</bold>
</p></list-item><list-item><p>To estimate the risk of contralateral breast cancer (CBC) in carriers of germline pathogenic variants (PVs) in <italic toggle="yes">ATM, BRCA1, BRCA2, CHEK2</italic>, and <italic toggle="yes">PALB2</italic> from prospective studies.</p></list-item><list-item><p>
<bold>Knowledge Generated</bold>
</p></list-item><list-item><p>Germline <italic toggle="yes">BRCA1, BRCA2</italic>, and <italic toggle="yes">CHEK2</italic> PV carriers with breast cancer were at a significantly elevated risk of CBC, whereas only the <italic toggle="yes">PALB2</italic> PV carriers with estrogen receptor&#8211;negative breast cancer had elevated risks. By contrast, <italic toggle="yes">ATM</italic> PV carriers did not have significantly increased CBC risks. African American PV carriers had similarly elevated risks of CBC as non-Hispanic White PV carriers. Age at diagnosis, menopausal status, and estrogen receptor status of the initial breast cancer significantly influenced the CBC risk in PV carriers.</p></list-item><list-item><p>
<bold>Relevance <italic toggle="yes">(K.D. Miller)</italic></bold>
</p></list-item><list-item><p>Patients with genetic mutations who have had an index breast cancer often assume that they are at high risk of developing another cancer in the other breast. The ability to better predict risk can guide decisions about prophylactic surgery and enhanced screening strategies for those who opt against bilateral mastectomy.*</p><p>*Relevance section written by <italic toggle="yes">JCO</italic> Senior Deputy Editor Kathy D. Miller, MD.</p></list-item></list>
</p></sec></boxed-text><p>Recently, the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium reported on germline genetic testing of &gt; 30,000 women with breast cancer and age-matched unaffected controls from US-based population-based studies.<sup><xref rid="b8" ref-type="bibr">8</xref></sup> Several contributing studies have prospective follow-up information on subsequent breast cancers, which presented a unique opportunity to study CBC risk among PV carriers in the general population. In addition, most women in these studies were unaware of their germline PV status at the time of breast cancer diagnosis, which permitted an unbiased assessment of the influence of germline PV status on CBC risk. In this article, we present CBC risk estimates among PV carriers from CARRIERS.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study Population</title><p>The CARRIERS consortium included 10 prospective studies with information on CBC after an initial breast cancer diagnosis (Data Supplement, online only). Women were enrolled at or before breast cancer diagnosis, except in the Two Sisters study, which enrolled up to four years after a breast cancer diagnosis. All studies prospectively followed women for CBC events from the time of enrollment. Baseline and follow-up questionnaires along with abstraction of medical records and linkage to state cancer registries were used for the assessment of CBC and covariates (Data Supplement). Women undergoing ipsilateral surgery for initial invasive breast cancer with at least one year of follow-up after initial breast cancer diagnosis were included (Data Supplement). Women diagnosed with bilateral breast cancer (CBC at initial diagnosis or within one year of initial diagnosis), undergoing bilateral mastectomy for initial breast cancer, or missing age at initial breast cancer or CBC diagnosis or with unknown CBC status at last follow-up were excluded. Both in situ and invasive breast cancers were considered CBC events. The patient selection schema is shown in the Data Supplement. The study was approved by the Mayo Clinic Institutional Review Board.</p></sec><sec><title>Germline Sequencing and Bioinformatics Analysis</title><p>Germline DNA samples were subjected to multiplex amplicon&#8211;based analysis covering all coding regions and consensus splice sites of established predisposition genes using a QIAseq custom panel (Data Supplement). Genetic variants were identified using the Genome Analysis Toolkit (GATK) Haplotype Caller and VarDict as described previously<sup><xref rid="b8" ref-type="bibr">8</xref>,<xref rid="b11" ref-type="bibr">11</xref></sup> (Data Supplement). Loss-of-function variants and pathogenic or likely pathogenic variants in the ClinVar database were classified as PVs. Since missense and low-penetrance variants in <italic toggle="yes">CHEK2</italic> have a lower risk of breast cancer than truncating variants,<sup><xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b13" ref-type="bibr">13</xref></sup> these were excluded from the primary analysis. CBC risks associated with missense variants and the low penetrance <italic toggle="yes">CHEK2</italic> p.Ile157Thr (c.470T&gt;C) variant were evaluated separately.<sup><xref rid="b12" ref-type="bibr">12</xref></sup></p></sec><sec><title>Statistical Analysis</title><p>The rates of CBC for carriers of PVs in each of the five genes (Separately for <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic>) were compared with the rates in women without germline PVs in the five genes in a time-to-event analysis beginning at the time of first breast cancer diagnosis and adjusting for competing risk of death using the Fine and Gray method.<sup><xref rid="b14" ref-type="bibr">14</xref></sup> Censoring occurred at the last follow-up or at contralateral prophylactic mastectomy (CPM, n = 57), whichever came first. The 5-, 10-, and 15-year risks of CBC for each gene were estimated from cumulative incidence curves. A multivariate proportional hazard regression analysis accounting for competing risk of death<sup><xref rid="b15" ref-type="bibr">15</xref></sup> was performed to compare the CBC risk between PV carriers in each of the five genes and non-PV carriers when adjusting for study, age of diagnosis,<sup><xref rid="b16" ref-type="bibr">16</xref>-<xref rid="b18" ref-type="bibr">18</xref></sup> race/ethnicity,<sup><xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b20" ref-type="bibr">20</xref></sup> menopausal status,<sup><xref rid="b21" ref-type="bibr">21</xref></sup> histology<sup><xref rid="b22" ref-type="bibr">22</xref>,<xref rid="b23" ref-type="bibr">23</xref></sup> and estrogen receptor (ER) status<sup><xref rid="b24" ref-type="bibr">24</xref></sup> of the first breast cancer, and use of endocrine therapy. Further analyses stratified by ER status, menopausal status, race/ethnicity, and age of diagnosis of first breast cancer were performed, adjusting for all relevant covariates in the original model. To account for the effect of ipsilateral breast cancer recurrence or second (nonbreast) cancers, sensitivity analysis censoring at ipsilateral recurrence, second (nonbreast) cancer, CPM, or last follow-up, whichever came first, was performed for studies with information on second cancers. All statistical analyses were performed in R, and the survival package cmprisk was used for analyses using competing risk of death.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec sec-type="subjects"><title>Patient Characteristics</title><p>A total of 15,104 women were included in the final analysis. The median age at diagnosis of initial breast cancer was 62 years, and the median follow-up was 11 years. Approximately 66% were non-Hispanic White (NHW), whereas 15% were African American. Women with ER-negative primary breast cancer were more likely to be African American, younger, and premenopausal at initial diagnosis compared with women with ER-positive breast cancer (Table <xref rid="tbl1" ref-type="table">1</xref>). The frequency of germline PVs in <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, or <italic toggle="yes">PALB2</italic> was 4.4% for the overall study and 3.7% and 7.4% for the ER-positive and ER-negative subsets, respectively. The study population was similar to the overall CARRIERS study<sup><xref rid="b8" ref-type="bibr">8</xref></sup> in terms of the median age at diagnosis, proportion of ER-negative tumors, and frequency of germline PVs although the proportion of Black, Hispanic, and Asian women was higher in the current study.</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>TABLE 1.</label><caption><p>Characteristics of the Study Population by ER Status at Initial Breast Cancer Diagnosis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jco-41-1703-g001.jpg"/></table-wrap></sec><sec><title>CBC Risks for PV Carriers Overall and by ER Status</title><p>A total of 801 CBC events were observed during follow-up, with 90 events (11.2%) in carriers of <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> PVs (Table <xref rid="tbl2" ref-type="table">2</xref>). In adjusted analysis, women with germline PVs in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, and <italic toggle="yes">CHEK2</italic> had a significantly increased risk (<italic toggle="yes">P</italic> &lt; .05) of CBC compared with women without PVs (Table <xref rid="tbl2" ref-type="table">2</xref>). In particular, <italic toggle="yes">BRCA1</italic> PV carriers had a 2.7-fold increased risk of CBC (hazard ratio [HR], 2.7; 95% CI, 2.0 to 3.8; <italic toggle="yes">P</italic> &lt; .001) and <italic toggle="yes">BRCA2</italic> PV carriers had a 3.0-fold increased risk (HR, 3.0; 95% CI, 2.1 to 4.3; <italic toggle="yes">P</italic> &lt; .001). Furthermore, <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> PV carriers with both ER-positive and ER-negative breast cancer had a significantly increased risk of CBC (Table <xref rid="tbl2" ref-type="table">2</xref>). Germline <italic toggle="yes">CHEK2</italic> PV carriers had a 1.9-fold elevated risk of CBC overall (HR, 1.9; 95% CI, 1.1 to 3.3; <italic toggle="yes">P</italic> = .03) and a 2-fold increased risk of CBC among those with ER-positive breast cancer (HR, 2.0; 95% CI, 1.1 to 3.5; <italic toggle="yes">P</italic> = .02). Similar results were observed for carriers of the common c.1100delC <italic toggle="yes">CHEK2</italic> PV (Table <xref rid="tbl2" ref-type="table">2</xref>). However, combined analysis of women with <italic toggle="yes">CHEK2</italic> truncating variants (n = 140), pathogenic or likely pathogenic missense variants, or missense variants predicted to be deleterious by functional assays<sup><xref rid="b25" ref-type="bibr">25</xref>,<xref rid="b26" ref-type="bibr">26</xref></sup> (n = 24) yielded a slightly lower risk of CBC (HR, 1.7; 95% CI, 0.9 to 2.9; <italic toggle="yes">P</italic> = .08). Furthermore, the <italic toggle="yes">CHEK2</italic> p.Ile157Thr (c.470T&gt;C) variant was not significantly associated with CBC risk in the overall (HR, 1.3; 95% CI, 0.5 to 3.4; <italic toggle="yes">P</italic> = .60) or the ER-positive subset (HR, 1.1; 95% CI, 0.3 to 3.3; <italic toggle="yes">P</italic> = .90). Although <italic toggle="yes">PALB2</italic> PV carriers did not have a significantly increased risk of CBC overall, the risk was significantly increased among <italic toggle="yes">PALB2</italic> PV carriers with ER-negative primary breast cancer (HR, 2.9; 95% CI, 1.4 to 6.4; <italic toggle="yes">P</italic> = .006). By contrast, here was only one CBC event during follow-up of 54 <italic toggle="yes">PALB2</italic> PV carriers with ER-positive breast cancer (Table <xref rid="tbl2" ref-type="table">2</xref>). Germline <italic toggle="yes">ATM</italic> PV carriers were not at significantly elevated risk of CBC overall (HR, 1.2; 95% CI, 0.6 to 2.6; <italic toggle="yes">P</italic> = .56) or among those with ER-positive disease.</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>TABLE 2.</label><caption><p>Contralateral Breast Cancer Risk Among Germline PV Carriers by ER Status</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jco-41-1703-g002.jpg"/></table-wrap><p>CBC risks among 14,237 women with breast cancer from the general population were also evaluated (Data Supplement). These women were slightly older and more likely postmenopausal than those in the overall CARRIERS study population (Data Supplement). The estimated CBC risks for PV carriers in the general population were similar to results from the overall analysis (<italic toggle="yes">BRCA1</italic> HR, 2.1, 95% CI, 1.2 to 3.5, <italic toggle="yes">P</italic> = .005; <italic toggle="yes">BRCA2</italic> HR, 2.5, 95% CI, 1.5 to 4.0, <italic toggle="yes">P</italic> &lt; .001; <italic toggle="yes">CHEK2</italic> ER-positive HR, 2.1, 95% CI, 1.1 to 4.1, <italic toggle="yes">P</italic> = .03; <italic toggle="yes">PALB2</italic> ER-negative HR, 3.1, 95% CI, 1.2 to 7.8, <italic toggle="yes">P</italic> = .02; Data Supplement). Sensitivity analysis for the general population, involving censoring at ipsilateral breast cancer recurrence and second (nonbreast) cancer, yielded results similar to those from the primary analysis (Data Supplement).</p></sec><sec><title>The Influence of Race, Menopausal Status, and Age at Diagnosis on CBC</title><p>The risks of CBC among NHW <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, and <italic toggle="yes">CHEK2</italic> PV carriers were similar to the overall study results. <italic toggle="yes">PALB2</italic> was uninformative because only one of the 49 NHW <italic toggle="yes">PALB2</italic> PV carriers developed CBC (Data Supplement). Among 2,249 African Americans with a breast cancer diagnosis, the risk of subsequent CBC was increased &gt; 2-fold for <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> PV carriers compared with noncarriers (<italic toggle="yes">BRCA1</italic> [HR, 2.5; 95% CI, 1.0 to 6.4; <italic toggle="yes">P</italic> = .06]; <italic toggle="yes">BRCA2</italic> [HR, 3.2; 95% CI, 1.5 to 6.9; <italic toggle="yes">P</italic> = .003]; <italic toggle="yes">CHEK2</italic> ER-positive [HR, 9.2; 95% CI, 2.9 to 28.9; <italic toggle="yes">P</italic> &lt; .001]; <italic toggle="yes">PALB2</italic> ER-negative [HR, 4.8; 95% CI, 1.4 to 16.8; <italic toggle="yes">P</italic> = .001]; Data Supplement). <italic toggle="yes">ATM</italic> PV carriers did not exhibit significantly increased risk of CBC in either race.</p><p>Exploratory analyses by menopausal status and age at diagnosis were also performed to understand the CBC risk among PV carriers. The frequencies of germline PVs in the five genes among 4,054 premenopausal and 11,050 postmenopausal women were 6.9% and 3.7%, respectively. In premenopausal women, PVs in <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> were associated with an increased risk of CBC in women with either ER-positive or ER-negative breast cancer, whereas <italic toggle="yes">CHEK2</italic> PVs were associated with an increased risk in only ER-positive and <italic toggle="yes">PALB2</italic> PVs with only ER-negative breast cancer (Table <xref rid="tbl3" ref-type="table">3</xref>). Despite the similar duration of follow-up and similar frequencies of <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> PV carriers among premenopausal and postmenopausal women (Data Supplement and Table <xref rid="tbl3" ref-type="table">3</xref>), the number of CBC events was lower in postmenopausal women, and <italic toggle="yes">BRCA2</italic> was the only gene associated with increased risk of CBC (HR, 3.0; 95% CI, 1.7 to 5.2; <italic toggle="yes">P</italic> &lt; .001; Table <xref rid="tbl3" ref-type="table">3</xref>). The frequency of germline PVs in <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> in 6,010 women diagnosed with initial breast cancer at &#8805; 65 years was 2.6% (Data Supplement). Despite a median follow-up of 10 years in this group, only three CBC events were observed, one each in <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, and <italic toggle="yes">PALB2</italic> PV carriers.</p><table-wrap position="float" id="tbl3" orientation="portrait"><label>TABLE 3.</label><caption><p>CBC Risk Among PV Carriers by Menopausal Status at Initial Breast Cancer Diagnosis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jco-41-1703-g003.jpg"/></table-wrap></sec><sec><title>Cumulative Incidence of CBC in PV Carriers</title><p>The cumulative incidence of CBC in women without germline PVs in the five genes was 2.2% in 5 years, 4.3% in 10 years, and 6.2% in 15 years, with an annualized cumulative incidence rate of approximately 0.4% per year (Fig <xref rid="fig1" ref-type="fig">1</xref>, Table <xref rid="tbl4" ref-type="table">4</xref>, and Data Supplement). Among <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> germline PV carriers, the 10-year cumulative incidences of CBC were 4.0%, 23.1%, 16.9%, 7.9%, and 7.9%, respectively. <italic toggle="yes">PALB2</italic> PV carriers with ER-negative breast cancer had a 10-year CBC risk of 19.7% (Table <xref rid="tbl3" ref-type="table">3</xref>). As expected, the 5-, 10-, and 15-year cumulative incidence of CBC among PV carriers was generally higher for premenopausal women although confidence intervals were wide. Importantly, the 15-year cumulative incidence of CBC among premenopausal women with PVs in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> (ER-negative) was &gt; 20% (Data Supplement).</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>FIG 1.</label><caption><p>Cumulative incidence of CBC risk in PV carriers. Cumulative incidence plots for first contralateral breast cancers after primary breast cancer. Cumulative incidence is plotted against years since first breast cancer. Stepped plots for non-PV carriers (red), and carriers of variants are (A) <italic toggle="yes">ATM</italic>; (B) <italic toggle="yes">BRCA1</italic>; (C) <italic toggle="yes">BRCA2</italic>; (D) <italic toggle="yes">CHEK2</italic>, all pathogenic; (E) <italic toggle="yes">CHEK2</italic> c.1100delC; and (F) <italic toggle="yes">PALB2</italic>. Numbers of carriers and noncarriers at each time point are displayed below the individual graphs. CBC, contralateral breast cancer; PV, pathogenic variant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jco-41-1703-g004.jpg"/></fig><table-wrap position="float" id="tbl4" orientation="portrait"><label>TABLE 4.</label><caption><p>Cumulative Incidence of Contralateral Breast Cancer by ER Status for PV Carriers</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jco-41-1703-g005.jpg"/></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In one of the largest prospective studies of CBC risk associated with germline PVs in predisposition genes, carriers of PVs in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, and <italic toggle="yes">CHEK2</italic> with breast cancer and carriers of <italic toggle="yes">PALB2</italic> PVs with ER-negative breast cancer were shown to be at increased risk of subsequent CBC, whereas carriers of <italic toggle="yes">ATM</italic> PVs did not have a statistically significantly elevated risk of CBC. The &gt; 2-fold increased risk of CBC and the 15-year cumulative incidence of approximately 30% and 25% for CBC after an initial breast cancer diagnosis for <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> PV carriers, respectively, are consistent with previous studies.<sup><xref rid="b6" ref-type="bibr">6</xref>,<xref rid="b27" ref-type="bibr">27</xref>-<xref rid="b31" ref-type="bibr">31</xref></sup> Although previous studies focused predominantly on CBC risks in high-risk women qualifying for genetic testing on the basis of young age of breast cancer diagnosis or family history, the current study showed that CBC risk was significantly elevated even among <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> PV carriers with breast cancer in the general population. The median age at diagnosis of breast cancer and the annualized cumulative incidence of 0.4% per year for CBC among noncarriers in the study were consistent with other population-based studies from the United States,<sup><xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b32" ref-type="bibr">32</xref></sup> suggesting that the present study closely mirrors women with breast cancer in the general population. The assessment of CBC using time-to-event analysis in prospective studies from the United States and the exclusion of women with synchronous bilateral breast cancer or those undergoing bilateral mastectomy at initial breast cancer diagnosis are significant strengths of this study that contribute to clinically relevant CBC risk estimation for each gene.</p><p>The association with increased risk of CBC in <italic toggle="yes">CHEK2</italic> PV carriers is consistent with previous studies<sup><xref rid="b33" ref-type="bibr">33</xref>-<xref rid="b38" ref-type="bibr">38</xref></sup> although the strength of association in previous studies was variable and several studies evaluated the c.1100delC variant only. In the current study, the c.1100delC variant was the most commonly observed PV in <italic toggle="yes">CHEK2</italic> and was associated with an approximately two-fold increased risk of CBC, especially in women with ER-positive primary breast cancers. Inclusion of other truncating variants in <italic toggle="yes">CHEK2</italic> in the analysis resulted in a stronger association for CBC risk than with the c.1100delC variant alone, suggesting that all truncating variants in <italic toggle="yes">CHEK2</italic> likely contribute to CBC risk. However, addition of missense PVs to truncating variants led to attenuation of the CBC risk associated with <italic toggle="yes">CHEK2</italic>, which brings into question whether missense PVs in <italic toggle="yes">CHEK2</italic> contribute to CBC risk. Interestingly, the risk of CBC among African American <italic toggle="yes">CHEK2</italic> PV carriers appeared to be related primarily to truncating variants other than c.1100delC although the numbers of carriers and events were small in this subset. These findings are consistent with previous studies evaluating the risk of primary breast cancer among African American women with truncating variants in <italic toggle="yes">CHEK2</italic>.<sup><xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b20" ref-type="bibr">20</xref></sup></p><p>This study showed that ER status of the primary breast cancer provides important indications regarding the subsequent CBC risk for PV carriers, especially for women with <italic toggle="yes">PALB2</italic> PVs. Although <italic toggle="yes">PALB2</italic> PVs have been associated with increased risk of both primary ER-negative and ER-positive breast cancers,<sup><xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b8" ref-type="bibr">8</xref></sup> the CBC events among <italic toggle="yes">PALB2</italic> PV carriers were almost exclusively among women with ER-negative disease. The etiology for these findings is unknown, but several possibilities including the effect of endocrine therapy on CBC risk and role of other genetic factors such as family history and polygenic risk scores need to be further evaluated in future studies to understand the differential effect of CBC risk by ER status in <italic toggle="yes">PALB2</italic> PV carriers.</p><p>Extrapolating from the current recommendations for women at high risk of primary breast cancer,<sup><xref rid="b39" ref-type="bibr">39</xref>,<xref rid="b40" ref-type="bibr">40</xref></sup> the &gt; 20% 15-year cumulative incidence of CBC among premenopausal women with PVs in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> offers support for clinical practice guidelines that advise aggressive surveillance for CBC with supplemental magnetic resonance imaging (MRI) in addition to mammograms. By contrast, the lack of association with significantly increased risk of CBC in postmenopausal PV carriers over age 65 years suggests that supplemental MRI for CBC may be of low yield and that CPM may not provide benefit in this subset. The current ASCO guideline on management of hereditary breast cancer already supports supplemental MRI screening for subsequent CBC risk among breast cancer survivors with PVs in high- or moderate-risk genes.<sup><xref rid="b41" ref-type="bibr">41</xref></sup> However, the findings of this study suggest that a more individualized approach to supplemental MRI screening in PV carriers on the basis of age and menopausal status at initial breast cancer diagnosis is warranted.</p><p>Since there are no well-established thresholds of CBC risk for recommending CPM, it is unclear whether premenopausal breast cancer survivors with PVs in <italic toggle="yes">CHEK2</italic> or <italic toggle="yes">PALB2</italic> can benefit from CPM despite the significantly elevated risk of CBC. Even for <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> PV carriers with breast cancer, the role of CPM in improving overall survival is controversial<sup><xref rid="b42" ref-type="bibr">42</xref>-<xref rid="b46" ref-type="bibr">46</xref></sup> although it is considered an acceptable option to reduce CBC risk.<sup><xref rid="b41" ref-type="bibr">41</xref>,<xref rid="b47" ref-type="bibr">47</xref></sup> Ultimately, the decision to undergo CPM for PV carriers should be individualized on the basis of estimation of the CBC risk considering several factors such as age at diagnosis, menopausal status, race/ethnicity, ER status of the initial breast cancer, cosmetic outcomes, and patient preference. The present study provides clinically valuable estimates of CBC risk in PV carriers on the basis of several of these factors, which will aid in decision making on CPM and surveillance strategies.</p><p>The lack of a statistically significant association with CBC risk for <italic toggle="yes">ATM</italic> PV carriers in the overall ER status and race analyses is consistent with recent studies.<sup><xref rid="b48" ref-type="bibr">48</xref>-<xref rid="b50" ref-type="bibr">50</xref></sup> However, these results should be interpreted with caution because the HRs for <italic toggle="yes">ATM</italic> PV carriers were &gt; 1.5 in several subsets, including postmenopausal and NHW women with ER-positive breast cancer. By contrast, there were no CBC events among 16 African American <italic toggle="yes">ATM</italic> PV carriers. Overall, these findings argue against CPM for CBC risk reduction in <italic toggle="yes">ATM</italic> PV carriers and suggest that supplemental MRI for surveillance of CBC risk might play a limited role in specific subsets of <italic toggle="yes">ATM</italic> PV carriers.</p><p>To our knowledge, this is the largest study to prospectively evaluate the CBC risk in African American carriers of PVs in BC predisposition genes and establishes that African American women with PVs in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, or <italic toggle="yes">PALB2</italic> are at increased risk of CBC. However, the HRs for CBC associated with PVs in several genes appeared to be slightly higher among African American women compared with NHW, which may be due to younger age at breast cancer diagnosis and a higher proportion of premenopausal women among the African American cohort. On the basis of the results of this study, it appears that the surveillance and risk reduction strategies for CBC should be similar for NHW and African American PV carriers.</p><p>There are some limitations to this study. Despite being one of the largest studies of CBC in PV carriers, the numbers of PV carriers and events in some of the subset analyses were low, leading to wide confidence intervals for risk estimates. Some of these exploratory subset analyses should be interpreted with caution because the small sample and larger well-powered studies are needed to confirm these findings. Similarly, although CBC risk in African American PV carriers was evaluated, it was not possible to estimate CBC risk among Hispanic and Asian women because of low numbers of PV carriers. Finally, the lack of comprehensive data on lifestyle factors, exposure to hormonal agents, and treatment-related variables, including chemotherapy, hormonal therapy, and radiation, is a limitation although it is unclear whether these would be significantly different in PV carriers compared with noncarriers.</p><p>In conclusion, germline <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, and <italic toggle="yes">CHEK2</italic> PV carriers with breast cancer and <italic toggle="yes">PALB2</italic> PV carriers with ER-negative breast cancer are at significantly increased risk of CBC. Premenopausal PV carriers of these four genes are at a higher risk of CBC compared with postmenopausal carriers, whereas the CBC risk in PV carriers among women over age 65 years appears to be similar to noncarriers. Among African American women, the risk of CBC also appears to be elevated in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic> PV carriers. Germline PVs in <italic toggle="yes">ATM</italic> are not associated with a significantly increased risk of CBC in this study regardless of age at diagnosis, menopausal status, or race/ethnicity. This study provides clinically meaningful guidance for surveillance and risk reduction strategies for CBC risk among breast cancer survivors who are carriers of PVs in breast cancer predisposition genes.</p></sec></body><back><fn-group content-type="disclaimer"><title>DISCLAIMER</title><fn specific-use="other" fn-type="other"><p>The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, the National Institutes of Health, or other funding sources.</p></fn></fn-group><fn-group content-type="supported-by"><title>SUPPORT</title><fn specific-use="supported-by" fn-type="supported-by"><p>Supported by NIH grants R01CA192393, R01CA225662, and R35CA253187 (F.J.C.); an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [P50CA116201] to Mayo Clinic; and the Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic [2K12CA090628-21]. Additional support for the contributing studies was provided by NIH awards (U01CA58860, H.A.-C.; UM1 CA164973; C.H.); NIEHS intramural awards (Z01-ES044005, Z01-ES049033, and Z01-ES102245, D.P.S. and C.R.W.); American Cancer Society; Susan G. Komen for the Cure (J.R.P., S.M.D., 2SISTER); Breast Cancer Research Foundation (F.J.C., J.M.W., S.M.D., and K.L.N.); Karin Grunebaum Cancer Research Foundation (J.R.P.); Lon V. Smith Foundation [LVS39420]; and The California Breast Cancer Research Fund (contract 97-10500), California Department of Public Health.</p></fn></fn-group><fn-group><fn specific-use="equal" fn-type="equal"><label>*</label><p>S.Y. and N.J.B. contributed equally to this work.</p></fn></fn-group><sec sec-type="contributed"><title>AUTHOR CONTRIBUTIONS</title><p><bold>Conception and design:</bold> Siddhartha Yadav, Nicholas J. Boddicker, Steven N. Hart, Jack A. Taylor, Hoda Anton-Culver, David E. Goldgar, Susan M. Domchek, Katherine L. Nathanson, Peter Kraft, Fergus J. Couch</p><p><bold>Financial support:</bold> Katherine L. Nathanson, Fergus J. Couch</p><p><bold>Administrative support:</bold> Nicole Larson, Susan Holtegaard, Katie M. O'Brien, Jeffrey N. Weitzel, Fergus J. Couch</p><p><bold>Provision of study materials or patients:</bold> Nicole Larson, Lauren R. Teras, Susan L. Neuhausen, Elena Martinez, Christopher Haiman, Fei Chen, Janet E. Olson, Clarice R. Weinberg, Julie R. Palmer</p><p><bold>Collection and assembly of data:</bold> Siddhartha Yadav, Nicholas J. Boddicker, Eric C. Polley, Chunling Hu, Nicole Larson, Susan Holtegaard, Carolyn A. Dunn, Lauren R. Teras, Alpa V. Patel, James V. Lacey, Susan L. Neuhausen, Elena Martinez, Christopher Haiman, Fei Chen, Janet E. Olson, Esther M. John, Dale P. Sandler, Jack A. Taylor, Clarice R. Weinberg, Hoda Anton-Culver, Argyrios Ziogas, Julie R. Palmer, Jeffrey N. Weitzel, Katherine L. Nathanson, Peter Kraft, Fergus J. Couch</p><p><bold>Data analysis and interpretation:</bold> Siddhartha Yadav, Nicholas J. Boddicker, Jie Na, Eric C. Polley, Chunling Hu, Steven N. Hart, Rohan D. Gnanaolivu, Huaizhi Huang, Carolyn A. Dunn, Kathryn J. Ruddy, Janet E. Olson, Allison W. Kurian, Dale P. Sandler, Katie M. O'Brien, Jack A. Taylor, Gary Zirpoli, Julie R. Palmer, Susan M. Domchek, Jeffrey N. Weitzel, Katherine L. Nathanson, Peter Kraft, Fergus J. Couch</p><p><bold>Manuscript writing:</bold> All authors</p><p><bold>Final approval of manuscript:</bold> All authors</p><p><bold>Accountable for all aspects of the work:</bold> All authors</p></sec><sec sec-type="COI-statement"><title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title><sec><title>Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">PALB2</italic></title><p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ascopubs.org/jco/authors/author-center" ext-link-type="uri">ascopubs.org/jco/authors/author-center</ext-link>.</p><p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p></sec><fn-group content-type="COI-statement"><fn id="con1" specific-use="other" fn-type="other"><p>
<bold>Siddhartha Yadav</bold>
</p><p><bold>Open Payments Link:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openpaymentsdata.cms.gov/physician/1025796" ext-link-type="uri">https://openpaymentsdata.cms.gov/physician/1025796</ext-link></p></fn><fn id="con2" specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Eric C. Polley</bold>
</p><p><bold>Research Funding:</bold> Grail</p></fn><fn id="con3" specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Alpa V. Patel</bold>
</p><p><bold>Research Funding:</bold> Grail (Inst)</p></fn><fn id="con4" specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Kathryn J. Ruddy</bold>
</p><p><bold>Research Funding:</bold> Medtronic</p><p><bold>Patents, Royalties, Other Intellectual Property:</bold> Spouse and Mayo Clinic have filed patents related to the application of artificial intelligence to the electrocardiogram for diagnosis and risk stratification</p></fn><fn id="con5" specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Janet E. Olson</bold>
</p><p><bold>Research Funding:</bold> Exact Sciences</p></fn><fn id="con6" specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Allison W. Kurian</bold>
</p><p><bold>Research Funding:</bold> Myriad Genetics (Inst)</p><p><bold>Other Relationship:</bold> Ambry Genetics, Color Genomics, GeneDx/BioReference, Invitae, Genentech</p></fn><fn id="con7" specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Susan M. Domchek</bold>
</p><p><bold>Honoraria:</bold> AstraZeneca, GlaxoSmithKline</p><p><bold>Research Funding:</bold> AstraZeneca (Inst), Clovis Oncology (Inst)</p><p><bold>Open Payments Link:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openpaymentsdata.cms.gov/physician/917904" ext-link-type="uri">https://openpaymentsdata.cms.gov/physician/917904</ext-link></p></fn><fn id="con8" specific-use="other" fn-type="other"><p>
<bold>Jeffrey N. Weitzel</bold>
</p><p><bold>Employment:</bold> Natera</p><p><bold>Stock and Other Ownership Interests:</bold> Natera</p><p><bold>Consulting or Advisory Role:</bold> Myriad Genetics</p><p><bold>Speakers' Bureau:</bold> AstraZeneca</p></fn><fn id="con9" specific-use="other" fn-type="other"><p>
<bold>Katherine L. Nathanson</bold>
</p><p><bold>Consulting or Advisory Role:</bold> Merck</p></fn><fn id="con10" specific-use="other" fn-type="other"><p>
<bold>Peter Kraft</bold>
</p><p><bold>Travel, Accommodations, Expenses:</bold> Regeneron</p></fn><fn id="con11" specific-use="conflict" fn-type="COI-statement"><p>
<bold>Fergus J. Couch</bold>
</p><p><bold>Honoraria:</bold> Ambry Genetics/Konica Minolta, US Oncology Network, Natera</p><p><bold>Consulting or Advisory Role:</bold> AstraZeneca</p><p><bold>Speakers' Bureau:</bold> Ambry Genetics, Qiagen</p><p><bold>Research Funding:</bold> Grail</p><p><bold>Travel, Accommodations, Expenses:</bold> Grail</p><p><bold>Other Relationship:</bold> Ambry Genetics</p><p>No other potential conflicts of interest were reported.</p></fn></fn-group></sec><notes><fn-group content-type="COI-statement"><fn specific-use="other" fn-type="other"><p>
<bold>Siddhartha Yadav</bold>
</p><p><bold>Open Payments Link:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openpaymentsdata.cms.gov/physician/1025796" ext-link-type="uri">https://openpaymentsdata.cms.gov/physician/1025796</ext-link></p></fn><fn specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Eric C. Polley</bold>
</p><p><bold>Research Funding:</bold> Grail</p></fn><fn specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Alpa V. Patel</bold>
</p><p><bold>Research Funding:</bold> Grail (Inst)</p></fn><fn specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Kathryn J. Ruddy</bold>
</p><p><bold>Research Funding:</bold> Medtronic</p><p><bold>Patents, Royalties, Other Intellectual Property:</bold> Spouse and Mayo Clinic have filed patents related to the application of artificial intelligence to the electrocardiogram for diagnosis and risk stratification</p></fn><fn specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Janet E. Olson</bold>
</p><p><bold>Research Funding:</bold> Exact Sciences</p></fn><fn specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Allison W. Kurian</bold>
</p><p><bold>Research Funding:</bold> Myriad Genetics (Inst)</p><p><bold>Other Relationship:</bold> Ambry Genetics, Color Genomics, GeneDx/BioReference, Invitae, Genentech</p></fn><fn specific-use="financial-disclosure" fn-type="financial-disclosure"><p>
<bold>Susan M. Domchek</bold>
</p><p><bold>Honoraria:</bold> AstraZeneca, GlaxoSmithKline</p><p><bold>Research Funding:</bold> AstraZeneca (Inst), Clovis Oncology (Inst)</p><p><bold>Open Payments Link:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openpaymentsdata.cms.gov/physician/917904" ext-link-type="uri">https://openpaymentsdata.cms.gov/physician/917904</ext-link></p></fn><fn specific-use="other" fn-type="other"><p>
<bold>Jeffrey N. Weitzel</bold>
</p><p><bold>Employment:</bold> Natera</p><p><bold>Stock and Other Ownership Interests:</bold> Natera</p><p><bold>Consulting or Advisory Role:</bold> Myriad Genetics</p><p><bold>Speakers' Bureau:</bold> AstraZeneca</p></fn><fn specific-use="other" fn-type="other"><p>
<bold>Katherine L. Nathanson</bold>
</p><p><bold>Consulting or Advisory Role:</bold> Merck</p></fn><fn specific-use="other" fn-type="other"><p>
<bold>Peter Kraft</bold>
</p><p><bold>Travel, Accommodations, Expenses:</bold> Regeneron</p></fn><fn specific-use="conflict" fn-type="COI-statement"><p>
<bold>Fergus J. Couch</bold>
</p><p><bold>Honoraria:</bold> Ambry Genetics/Konica Minolta, US Oncology Network, Natera</p><p><bold>Consulting or Advisory Role:</bold> AstraZeneca</p><p><bold>Speakers' Bureau:</bold> Ambry Genetics, Qiagen</p><p><bold>Research Funding:</bold> Grail</p><p><bold>Travel, Accommodations, Expenses:</bold> Grail</p><p><bold>Other Relationship:</bold> Ambry Genetics</p><p>No other potential conflicts of interest were reported.</p></fn></fn-group></notes><ref-list><title>REFERENCES</title><ref id="b1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Emami</surname><given-names>B</given-names></name></person-group>: <article-title>Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study</article-title>. <source>Int J Radiat Oncol Biol Phys</source><volume>56</volume>:<fpage>1038</fpage>-<lpage>1045</lpage>, <year>2003</year><pub-id pub-id-type="pmid">12829139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0360-3016(03)00203-7</pub-id></mixed-citation></ref><ref id="b2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Withrow</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Davis Lynn</surname><given-names>BC</given-names></name>, <etal>et al</etal></person-group>: <article-title>Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992&#8211;2016</article-title>. <source>Breast Cancer Res</source><volume>23</volume>:<fpage>24</fpage>, <year>2021</year><pub-id pub-id-type="pmid">33596988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-021-01400-3</pub-id><pub-id pub-id-type="pmcid">PMC7890613</pub-id></mixed-citation></ref><ref id="b3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kramer</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hooning</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Mavaddat</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>: <article-title>Breast cancer polygenic risk score and contralateral breast cancer risk</article-title>. <source>Am J Hum Genet</source><volume>107</volume>:<fpage>837</fpage>-<lpage>848</lpage>, <year>2020</year><pub-id pub-id-type="pmid">33022221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2020.09.001</pub-id><pub-id pub-id-type="pmcid">PMC7675034</pub-id></mixed-citation></ref><ref id="b4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiner</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Sisti</surname><given-names>J</given-names></name>, <name name-style="western"><surname>John</surname><given-names>EM</given-names></name>, <etal>et al</etal></person-group>: <article-title>Breast cancer family history and contralateral breast cancer risk in young women: An update from the Women's Environmental Cancer and Radiation Epidemiology study</article-title>. <source>J Clin Oncol</source><volume>36</volume>:<fpage>1513</fpage>-<lpage>1520</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29620998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.77.3424</pub-id><pub-id pub-id-type="pmcid">PMC5959199</pub-id></mixed-citation></ref><ref id="b5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Semenciw</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>Epidemiology of contralateral breast cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source><volume>8</volume>:<fpage>855</fpage>-<lpage>861</lpage>, <year>1999</year><pub-id pub-id-type="pmid">10548312</pub-id></mixed-citation></ref><ref id="b6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuchenbaecker</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Hopper</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Barnes</surname><given-names>DR</given-names></name>, <etal>et al</etal></person-group>: <article-title>Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers</article-title>. <source>JAMA</source><volume>317</volume>:<fpage>2402</fpage>-<lpage>2416</lpage>, <year>2017</year><pub-id pub-id-type="pmid">28632866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.7112</pub-id></mixed-citation></ref><ref id="b7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Breast Cancer Association Consortium</collab>, <name name-style="western"><surname>Dorling</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Carvalho</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>: <article-title>Breast cancer risk genes&#8212;Association analysis in more than 113,000 women</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>428</fpage>-<lpage>439</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33471991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1913948</pub-id><pub-id pub-id-type="pmcid">PMC7611105</pub-id></mixed-citation></ref><ref id="b8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hart</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Gnanaolivu</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>A population-based study of genes previously implicated in breast cancer</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>440</fpage>-<lpage>451</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33471974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2005936</pub-id><pub-id pub-id-type="pmcid">PMC8127622</pub-id></mixed-citation></ref><ref id="b9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Couch</surname><given-names>FJ</given-names></name></person-group>: <article-title>Germline genetic testing for breast cancer risk: The past, present, and future</article-title>. <source>Am Soc Clin Oncol Ed Book</source><volume>39</volume>:<fpage>61</fpage>-<lpage>74</lpage>, <year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/EDBK_238987</pub-id><pub-id pub-id-type="pmid">31099663</pub-id></mixed-citation></ref><ref id="b10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Polley</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>: <article-title>Contribution of germline predisposition gene mutations to breast cancer risk in African American women</article-title>. <source>J Natl Cancer Inst</source><volume>112</volume>:<fpage>1213</fpage>-<lpage>1221</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32427313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djaa040</pub-id><pub-id pub-id-type="pmcid">PMC7735769</pub-id></mixed-citation></ref><ref id="b11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hart</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>: <article-title>Contribution of inherited DNA-repair gene mutations to hormone-sensitive and castrate-resistant metastatic prostate cancer and implications for clinical outcome</article-title>. <source>JCO Precis Oncol</source><volume>3</volume>:<fpage>1</fpage>-<lpage>12</lpage>, <year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.19.00067</pub-id><pub-id pub-id-type="pmcid">PMC7446380</pub-id><pub-id pub-id-type="pmid">32923857</pub-id></mixed-citation></ref><ref id="b12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilpivaara</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Vahteristo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Falck</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>CHEK2 variant I157T may be associated with increased breast cancer risk</article-title>. <source>Int J Cancer</source><volume>111</volume>:<fpage>543</fpage>-<lpage>547</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15239132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.20299</pub-id></mixed-citation></ref><ref id="b13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorling</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Carvalho</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Allen</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>Breast cancer risks associated with missense variants in breast cancer susceptibility genes</article-title>. <source>Genome Med</source><volume>14</volume>:<fpage>51</fpage>, <year>2022</year><pub-id pub-id-type="pmid">35585550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-022-01052-8</pub-id><pub-id pub-id-type="pmcid">PMC9116026</pub-id></mixed-citation></ref><ref id="b14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>JG</given-names></name></person-group>: <article-title>A class of $K$-Sample tests for comparing the cumulative incidence of a competing risk</article-title>. <source>Ann Stat</source><volume>16</volume>:<fpage>1141</fpage>-<lpage>1154</lpage>, <year>1988</year></mixed-citation></ref><ref id="b15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fine</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>RJ</given-names></name></person-group>: <article-title>A proportional hazards model for the subdistribution of a competing risk</article-title>. <source>J Am Stat Assoc</source><volume>94</volume>:<fpage>496</fpage>-<lpage>509</lpage>, <year>1999</year></mixed-citation></ref><ref id="b16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>TI</given-names></name>, <name name-style="western"><surname>Kwak</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Yi</surname><given-names>OV</given-names></name>, <etal>et al</etal></person-group>: <article-title>Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women</article-title>. <source>Breast Cancer Res Treat</source><volume>173</volume>:<fpage>657</fpage>-<lpage>665</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30377870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-018-5031-4</pub-id></mixed-citation></ref><ref id="b17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boddicker</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Weitzel</surname><given-names>JN</given-names></name>, <etal>et al</etal></person-group>: <article-title>Risk of late-onset breast cancer in genetically predisposed women</article-title>. <source>J Clin Oncol</source><volume>39</volume>:<fpage>3430</fpage>-<lpage>3440</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34292776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.00531</pub-id><pub-id pub-id-type="pmcid">PMC8547938</pub-id></mixed-citation></ref><ref id="b18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hart</surname><given-names>SN</given-names></name>, <etal>et al</etal></person-group>: <article-title>Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer</article-title>. <source>J Clin Oncol</source><volume>38</volume>:<fpage>1409</fpage>-<lpage>1418</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32125938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.19.02190</pub-id><pub-id pub-id-type="pmcid">PMC7193748</pub-id></mixed-citation></ref><ref id="b19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watt</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>John</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Bandera</surname><given-names>EV</given-names></name>, <etal>et al</etal></person-group>: <article-title>Race, ethnicity and risk of second primary contralateral breast cancer in the United States</article-title>. <source>Int J Cancer</source><volume>148</volume>:<fpage>2748</fpage>-<lpage>2758</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33544892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33501</pub-id><pub-id pub-id-type="pmcid">PMC9059169</pub-id></mixed-citation></ref><ref id="b20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>S</given-names></name>, <name name-style="western"><surname>LaDuca</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Polley</surname><given-names>EC</given-names></name>, <etal>et al</etal></person-group>: <article-title>Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer</article-title>. <source>J Natl Cancer Inst</source><volume>113</volume>:<fpage>1429</fpage>-<lpage>1433</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33146377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djaa167</pub-id><pub-id pub-id-type="pmcid">PMC8633452</pub-id></mixed-citation></ref><ref id="b21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cook</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>White</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>SM</given-names></name>, <etal>et al</etal></person-group>: <article-title>A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States)</article-title>. <source>Cancer Causes and Control</source><volume>7</volume>:<fpage>382</fpage>-<lpage>390</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8734833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00052945</pub-id></mixed-citation></ref><ref id="b22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Nathanson</surname><given-names>KL</given-names></name>, <etal>et al</etal></person-group>: <article-title>Germline pathogenic variants in cancer predisposition genes among women with invasive lobular carcinoma of the breast</article-title>. <source>J Clin Oncol</source><volume>39</volume>:<fpage>3918</fpage>-<lpage>3926</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34672684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.00640</pub-id><pub-id pub-id-type="pmcid">PMC8660003</pub-id></mixed-citation></ref><ref id="b23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Glas</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Engels</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Bastiaannet</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>: <article-title>Contralateral breast cancer risk in relation to tumor morphology and age-in which patients is preoperative MRI justified?</article-title><source>Breast Cancer Res Treat</source><volume>150</volume>:<fpage>191</fpage>-<lpage>198</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25677741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-015-3294-6</pub-id><pub-id pub-id-type="pmcid">PMC4344552</pub-id></mixed-citation></ref><ref id="b24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiner</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Lynch</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Sisti</surname><given-names>JS</given-names></name>, <etal>et al</etal></person-group>: <article-title>Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population</article-title>. <source>Breast Cancer Res</source><volume>1983</volume>:<fpage>83</fpage>, <year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-017-0874-x</pub-id><pub-id pub-id-type="pmcid">PMC5517810</pub-id><pub-id pub-id-type="pmid">28724391</pub-id></mixed-citation></ref><ref id="b25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boonen</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Wiegant</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Celosse</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>: <article-title>Functional analysis identifies damaging CHEK2 missense variants associated with increased cancer risk</article-title>. <source>Cancer Res</source><volume>82</volume>:<fpage>615</fpage>-<lpage>631</lpage>, <year>2022</year><pub-id pub-id-type="pmid">34903604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-21-1845</pub-id><pub-id pub-id-type="pmcid">PMC9359737</pub-id></mixed-citation></ref><ref id="b26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleiblova</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Stolarova</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Krizova</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>: <article-title>Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer</article-title>. <source>Int J Cancer</source><volume>145</volume>:<fpage>1782</fpage>-<lpage>1797</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31050813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.32385</pub-id></mixed-citation></ref><ref id="b27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metcalfe</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gershman</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lynch</surname><given-names>HT</given-names></name>, <etal>et al</etal></person-group>: <article-title>Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers</article-title>. <source>Br J Cancer</source><volume>104</volume>:<fpage>1384</fpage>-<lpage>1392</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21487411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.2011.120</pub-id><pub-id pub-id-type="pmcid">PMC3101934</pub-id></mixed-citation></ref><ref id="b28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotsopoulos</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lubinski</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lynch</surname><given-names>HT</given-names></name>, <etal>et al</etal></person-group>: <article-title>Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers</article-title>. <source>Breast Cancer Res Treat</source><volume>175</volume>:<fpage>443</fpage>-<lpage>449</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30756284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-019-05162-7</pub-id></mixed-citation></ref><ref id="b29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lubinski</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Huzarski</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gronwald</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers</article-title>. <source>Breast Cancer Res Treat</source><volume>174</volume>:<fpage>769</fpage>-<lpage>774</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30612273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-018-05076-w</pub-id></mixed-citation></ref><ref id="b30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malone</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Haile</surname><given-names>RW</given-names></name>, <etal>et al</etal></person-group>: <article-title>Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2</article-title>. <source>J Clin Oncol</source><volume>28</volume>:<fpage>2404</fpage>-<lpage>2410</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20368571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2009.24.2495</pub-id><pub-id pub-id-type="pmcid">PMC2881721</pub-id></mixed-citation></ref><ref id="b31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molina-Montes</surname><given-names>E</given-names></name>, <name name-style="western"><surname>P&#233;rez-Nevot</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Poll&#225;n</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>: <article-title>Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis</article-title>. <source>Breast</source><volume>23</volume>:<fpage>721</fpage>-<lpage>742</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25467311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.breast.2014.10.005</pub-id></mixed-citation></ref><ref id="b32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>Nomogram to predict contralateral breast cancer risk in breast cancer survivors: A SEER-based study</article-title>. <source>Medicine</source><volume>100</volume>:<fpage>e27595</fpage>, <year>2021</year><pub-id pub-id-type="pmid">34797281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000027595</pub-id><pub-id pub-id-type="pmcid">PMC8601336</pub-id></mixed-citation></ref><ref id="b33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kriege</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hollestelle</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jager</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: Impact of adjuvant chemotherapy</article-title>. <source>Br J Cancer</source><volume>111</volume>:<fpage>1004</fpage>-<lpage>1013</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24918820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.2014.306</pub-id><pub-id pub-id-type="pmcid">PMC4150261</pub-id></mixed-citation></ref><ref id="b34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broeks</surname><given-names>A</given-names></name>, <name name-style="western"><surname>de Witte</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Nooijen</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers</article-title>. <source>Breast Cancer Res Treat</source><volume>83</volume>:<fpage>91</fpage>-<lpage>93</lpage>, <year>2004</year><pub-id pub-id-type="pmid">14997059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/B:BREA.0000010697.49896.03</pub-id></mixed-citation></ref><ref id="b35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Clifford</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>: <article-title>Prevalence of germline pathogenic and likely pathogenic variants in patients with second breast cancers</article-title>. <source>JNCI Cancer Spectr</source><volume>4</volume>:<fpage>pkaa094</fpage>, <year>2020</year><pub-id pub-id-type="pmid">33409458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jncics/pkaa094</pub-id><pub-id pub-id-type="pmcid">PMC7771422</pub-id></mixed-citation></ref><ref id="b36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akdeniz</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Seynaeve</surname><given-names>CM</given-names></name>, <etal>et al</etal></person-group>: <article-title>Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis</article-title>. <source>Breast</source><volume>44</volume>:<fpage>1</fpage>-<lpage>14</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30580169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.breast.2018.11.005</pub-id></mixed-citation></ref><ref id="b37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Bock</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Schutte</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Krol-Warmerdam</surname><given-names>EM</given-names></name>, <etal>et al</etal></person-group>: <article-title>Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant</article-title>. <source>J Med Genet</source><volume>41</volume>:<fpage>731</fpage>-<lpage>735</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15466005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.2004.019737</pub-id><pub-id pub-id-type="pmcid">PMC1735606</pub-id></mixed-citation></ref><ref id="b38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Tollenaar</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>de Kemp</surname><given-names>SR</given-names></name>, <etal>et al</etal></person-group>: <article-title>Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation</article-title>. <source>J Clin Oncol</source><volume>25</volume>:<fpage>64</fpage>-<lpage>69</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17132695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2006.06.3024</pub-id></mixed-citation></ref><ref id="b39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Monticciolo</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Moy</surname><given-names>L</given-names></name></person-group>: <article-title>Screening guidelines update for average-risk and high-risk women</article-title>. <source>Am J Roentgenol</source><volume>214</volume>:<fpage>316</fpage>-<lpage>323</lpage>, <year>2020</year><pub-id pub-id-type="pmid">31714845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.19.22205</pub-id></mixed-citation></ref><ref id="b40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saslow</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Boetes</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Burke</surname><given-names>W</given-names></name>, <etal>et al</etal></person-group>: <article-title>American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography</article-title>. <source>CA Cancer J Clin</source><volume>57</volume>:<fpage>75</fpage>-<lpage>89</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17392385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/canjclin.57.2.75</pub-id></mixed-citation></ref><ref id="b41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tung</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Boughey</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Pierce</surname><given-names>LJ</given-names></name>, <etal>et al</etal></person-group>: <article-title>Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline</article-title>. <source>J Clin Oncol</source><volume>38</volume>:<fpage>2080</fpage>-<lpage>2106</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32243226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.20.00299</pub-id></mixed-citation></ref><ref id="b42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Sprundel</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Rookus</surname><given-names>MA</given-names></name>, <etal>et al</etal></person-group>: <article-title>Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers</article-title>. <source>Br J Cancer</source><volume>93</volume>:<fpage>287</fpage>-<lpage>292</lpage>, <year>2005</year><pub-id pub-id-type="pmid">16052221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6602703</pub-id><pub-id pub-id-type="pmcid">PMC2361560</pub-id></mixed-citation></ref><ref id="b43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metcalfe</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gershman</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ghadirian</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>: <article-title>Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: Retrospective analysis</article-title>. <source>BMJ</source><volume>348</volume>:<fpage>g226</fpage>, <year>2014</year><pub-id pub-id-type="pmid">24519767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.g226</pub-id><pub-id pub-id-type="pmcid">PMC3921438</pub-id></mixed-citation></ref><ref id="b44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>You</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <etal>et al</etal></person-group>: <article-title>Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: A meta-analysis and systematic review</article-title>. <source>Clin Cancer Res</source><volume>22</volume>:<fpage>3971</fpage>-<lpage>3981</lpage>, <year>2016</year><pub-id pub-id-type="pmid">26979395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-15-1465</pub-id></mixed-citation></ref><ref id="b45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Copson</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Maishman</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Tapper</surname><given-names>WJ</given-names></name>, <etal>et al</etal></person-group>: <article-title>Germline BRCA mutation and outcome in young-onset breast cancer (POSH): A prospective cohort study</article-title>. <source>Lancet Oncol</source><volume>19</volume>:<fpage>169</fpage>-<lpage>180</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29337092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(17)30891-4</pub-id><pub-id pub-id-type="pmcid">PMC5805863</pub-id></mixed-citation></ref><ref id="b46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heemskerk-Gerritsen</surname><given-names>BAM</given-names></name>, <name name-style="western"><surname>Rookus</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Aalfs</surname><given-names>CM</given-names></name>, <etal>et al</etal></person-group>: <article-title>Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis</article-title>. <source>Int J Cancer</source><volume>136</volume>:<fpage>668</fpage>-<lpage>677</lpage>, <year>2015</year><pub-id pub-id-type="pmid">24947112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.29032</pub-id></mixed-citation></ref><ref id="b47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Pal</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Berry</surname><given-names>MP</given-names></name>, <etal>et al</etal></person-group>: <article-title>Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in Oncology</article-title>. <source>J Natl Compr Canc Netw</source><volume>19</volume>:<fpage>77</fpage>-<lpage>102</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33406487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2021.0001</pub-id></mixed-citation></ref><ref id="b48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiner</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Robson</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Mellemkj&#230;r</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>: <article-title>Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants and risk of contralateral breast cancer</article-title>. <source>J Natl Cancer Inst</source><volume>112</volume>:<fpage>1275</fpage>-<lpage>1279</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32119081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djaa031</pub-id><pub-id pub-id-type="pmcid">PMC7735763</pub-id></mixed-citation></ref><ref id="b49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broeks</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Braaf</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Huseinovic</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>The spectrum of ATM missense variants and their contribution to contralateral breast cancer</article-title>. <source>Breast Cancer Res Treat</source><volume>107</volume>:<fpage>243</fpage>-<lpage>248</lpage>, <year>2008</year><pub-id pub-id-type="pmid">17393301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-007-9543-6</pub-id><pub-id pub-id-type="pmcid">PMC2137941</pub-id></mixed-citation></ref><ref id="b50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weitzel</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Kidd</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bernhisel</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>Multigene assessment of genetic risk for women for two or more breast cancers</article-title>. <source>Breast Cancer Res Treat</source><volume>188</volume>:<fpage>759</fpage>-<lpage>768</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33826040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-021-06201-y</pub-id><pub-id pub-id-type="pmcid">PMC8803157</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>